AI company has its breast cancer and colorectal therapies approved for use in Europe
News
Avacta announces clinical study of AVA6000
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Manus Bio receives additional funding to combat malaria
Fourth award from the Bill & Melinda Gates Foundation will support artemisinin research
Kaiku Health enters wider partnership with Novartis
Following a successful collaboration, the companies will now partner to focus on precision medicine
Psyomics links up with Hertfordshire Partnership University NHS Foundation Trust
Hertfordshire Trust to invest in mental health care with wide-ranging digital assessment platform
European Commission approves pharma trio’s Ranivisio
Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union
Novartis’ Scemblix approved by the EC for adults with chronic myeloid leukaemia
It is estimated that every year more than 6,300 people will be diagnosed with CML in Europe
MIT’s AI model can detect Parkinson’s by tracking breathing patterns
The tool uses a series of connected algorithms that can assess if someone has PD from their nocturnal breathing
Pfizer’s RSV vaccine candidate shows promise in older adults study
It is estimated that RSV infections in older adults account for 177,000 hospitalisations and 14,000 deaths each year in the US alone
Janssen’s teclistamab gets CMA from European Commission
Teclistamab is the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma
Alpha Cognition announces bioequivalence study results for Alzheimer’s
In 2019, there were over 850,000 people with dementia in the UK, representing one in every 14 people aged 65 and over
Trial results for Pfizer and BioNTech’s COVID-19 vaccine for children released
The phase 2/3 trial results showed that the vaccine was effective in protecting children
Roche launches digital PCR system for ultra-rare and emerging diseases
Using the system, the researchers are able to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions
EMA accepts application for leukaemia drug from Otsuka and Astex
The marketing authorisation application is supported by results from a phase 3 trial for AML
EMA accepts Mundipharma’s application for candidiasis drug rezafungin
Despite current treatments, the mortality rate for patients with invasive candidiasis remains high
